Guardant Health, Inc. $GH Shares Acquired by Rathbones Group PLC

Rathbones Group PLC lifted its stake in Guardant Health, Inc. (NASDAQ:GH) by 1.9% during the second quarter, Holdings Channel reports. The institutional investor owned 205,965 shares of the company’s stock after acquiring an additional 3,838 shares during the quarter. Rathbones Group PLC’s holdings in Guardant Health were worth $10,718,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. IFP Advisors Inc lifted its holdings in Guardant Health by 120.1% in the second quarter. IFP Advisors Inc now owns 612 shares of the company’s stock valued at $33,000 after acquiring an additional 334 shares during the period. Signaturefd LLC grew its stake in shares of Guardant Health by 50.5% during the 2nd quarter. Signaturefd LLC now owns 635 shares of the company’s stock worth $33,000 after purchasing an additional 213 shares during the period. FNY Investment Advisers LLC purchased a new position in shares of Guardant Health during the 2nd quarter valued at approximately $62,000. SVB Wealth LLC acquired a new position in shares of Guardant Health in the 1st quarter valued at $54,000. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Guardant Health in the 1st quarter valued at $97,000. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently commented on the stock. Leerink Partners raised their price target on shares of Guardant Health from $70.00 to $75.00 and gave the company an “outperform” rating in a research report on Thursday, September 25th. Guggenheim raised their target price on Guardant Health from $56.00 to $67.00 and gave the company a “buy” rating in a research report on Thursday, September 25th. JPMorgan Chase & Co. lifted their price target on Guardant Health from $60.00 to $70.00 and gave the company an “overweight” rating in a research note on Thursday, September 25th. TD Cowen upped their price target on Guardant Health from $63.00 to $72.00 and gave the stock a “buy” rating in a report on Thursday, September 25th. Finally, Scotiabank raised their price objective on Guardant Health from $57.00 to $60.00 and gave the company a “sector outperform” rating in a report on Thursday, July 31st. Twenty-three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Guardant Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $77.14.

Insider Buying and Selling at Guardant Health

In other news, Director Medina Manuel Hidalgo sold 2,165 shares of the company’s stock in a transaction on Friday, September 12th. The shares were sold at an average price of $54.16, for a total transaction of $117,256.40. Following the completion of the sale, the director owned 851 shares of the company’s stock, valued at $46,090.16. This represents a 71.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Helmy Eltoukhy sold 300,000 shares of the stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $59.45, for a total transaction of $17,835,000.00. Following the completion of the sale, the chief executive officer owned 2,123,499 shares of the company’s stock, valued at $126,242,015.55. This trade represents a 12.38% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 302,691 shares of company stock valued at $17,984,628. 6.10% of the stock is owned by corporate insiders.

Guardant Health Trading Up 0.5%

GH stock opened at $96.72 on Monday. Guardant Health, Inc. has a 12-month low of $28.20 and a 12-month high of $100.22. The business’s 50-day moving average is $67.52 and its 200 day moving average is $55.11. The stock has a market cap of $12.19 billion, a price-to-earnings ratio of -30.13 and a beta of 1.56.

Guardant Health (NASDAQ:GH) last announced its earnings results on Wednesday, October 29th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.26). The business had revenue of $265.20 million during the quarter, compared to analyst estimates of $235.72 million. Guardant Health’s revenue was up 38.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.88) earnings per share. Guardant Health has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.